Committee for Medicinal Products for Human Use (CHMP) issues positive recommendation for generic version of azacitidine

Azacitidine Mylan and betapharm will be available as a powder for suspension for injection (25 mg/ml) for the same existing licensed indications as Vidaza branded azacitidine; and are the first generic preparations to be made available.


European Medicines Agency